Abstract
Patients with germ cell tumours who relapse or fail to achieve disease-free status after first-line chemotherapy have a poor prognosis. When administered orally, etoposide produces responses in approximately 25% of patients whose disease is refractory to therapy and is a reasonable choice for palliative treatment in patients who are otherwise incurable. Oral etoposide has also been studied as maintenance therapy in patients who have been treated with salvage chemotherapy or surgery, with results that compare favourably with historical data. We recommend 3 months of maintenance oral etoposide for patients who achieve a complete response to any type of salvage therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Einhorn LH, Richie JP, Shipley WU. Cancer of the testis. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993: 1126–51
Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777–81
Broun ER, Nichols CR, Kneebone P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124–8
Einhorn L, Weathers T, Loehrer P, et al. Long term follow-up of second line chemotherapy with vinblastine, ifosfamide and cisplatin in disseminated germ cell tumors. Proc Am Soc Clin Oncol 1996; 15: 240A
Newlands ES, Bagshawe KD. Epipodophyllin derivative (VP 16-213) in malignant teratomas and choriocarcinomas [letter]. Lancet 1977; 2: 87
Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–40
Cavalli F, Klepp O, Renard J, et al. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer. Eur J Cancer 1981; 17: 245–9
Miller JL, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17 Suppl. 1: 36–9
Cooper M, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 1995; 13: 1167–9
Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540–6
Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11: 324–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saxman, S. Oral Etoposide in Germ Cell Tumours. Drugs 58 (Suppl 3), 31–34 (1999). https://doi.org/10.2165/00003495-199958003-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958003-00005